December 18, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced that it has completed patient dosing for its Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD)...Allon’s program is also the first clinical program to show an effect in animals on both of the classic hallmarks of Alzheimer’s: Neurofibrillary tangles and amyloid beta plaques... Allon's Press Release -
Monday, January 7, 2008
Allon Therapeutics, Phase II clinical trial in Alzheimer’s program
December 18, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced that it has completed patient dosing for its Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD)...Allon’s program is also the first clinical program to show an effect in animals on both of the classic hallmarks of Alzheimer’s: Neurofibrillary tangles and amyloid beta plaques... Allon's Press Release -
